ArticleHealth science reports2026
Red Cell and Platelet Indices as Biomarkers of Poor Glycemic Control in Patients With Type 2 Diabetes: A Case-Control Study.
Article in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aim: Type 2 diabetes mellitus (T2DM) is associated with systemic inflammation and altered hematological function, including changes in red cell indices and platelet hyperreactivity. While glycosylated hemoglobin (HbA1c) is the gold standard for monitoring glycemic control, its cost and susceptibility to conditions like anemia highlight the need for accessible, reliable alternative biomarkers, particularly for identifying patients with poor glycemic control (HbA1c ≥ 7.0%). This case-control study, therefore, investigated the utility of red cell and platelet indices as potential biomarkers of poor glycemic control in Ghanaian T2DM patients. Methods: This study recruited 134 people living with T2DM and 134 nondiabetic controls. Cases were categorized into groups with poor glycemic control (HbA1c ≥ 7.0%) and good glycemic control (HbA1c < 7.0%). HbA1c was measured using an automated analyzer, and hematological indices were measured using a Sysmex XN 2000 analyzer. Statistical analyses were performed in R Language and SPSS version 26 at a significance level of 0.05% and 95% confidence interval employing a logistic prediction model. Results: Prevalence of poor glycemic control was 60.9%. Cases with poor glycemic control had significantly lower red cell indices such as hemoglobin, hematocrit, red blood cells count, and MCV, but a higher MPV compared to controls ( Conclusion: Hemoglobin level, hematocrit, and mean platelet volume are significantly associated with, and can potentially serve as independent predictors of poor glycemic control. These routine, cost-effective hematological parameters could be incorporated into risk assessment and management protocols for T2DM in resource-limited settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.